Please login to the form below

Not currently logged in
Email:
Password:

CTI Biopharma

This page shows the latest CTI Biopharma news and features for those working in and with pharma, biotech and healthcare.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma

and aminopeptidase inhibitor tosedostat for leukaemia, which is partnered with CTI Biopharma.

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure. ... gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve

  • Baxalta and CTI complete filing for Jakafi rival in US Baxalta and CTI complete filing for Jakafi rival in US

    Myelofibrosis candidate pacritinib aiming for accelerated approval. Baxalta and CTI Biopharma have completed their rolling regulatory submission for their myelofibrosis candidate pacritinib in the US, and are aiming for accelerated approval.

  • Baxter and CTI's Jakafi rival clears phase III trial Baxter and CTI's Jakafi rival clears phase III trial

    Myelofibrosis candidate pacritinib moves closer to market.  . Baxter and CTI Biopharma have moved a step closer to bringing their myelofibrosis candidate pacritinib to market after reporting positive results in a phase ... Baxter licensed rights to

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics